Laboratory of Experimental Carcinogenesis (LEC), Center for Cancer Research, National Cancer Institute, NIH.
Department of Medicine I, Johannes Gutenberg University, Mainz, Germany.
J Hepatol. 2014 Feb;60(2):346-353. doi: 10.1016/j.jhep.2013.10.014. Epub 2013 Oct 26.
BACKGROUND & AIMS: Human hepatocarcinogenesis is as a multi-step process starting from dysplastic lesions to early carcinomas (eHCC) that ultimately progress to HCC (pHCC). However, the sequential molecular alterations driving malignant transformation of the pre-neoplastic lesions are not clearly defined. This lack of information represents a major challenge in the clinical management of patients at risk.
We applied next-generation transcriptome sequencing to tumor-free surrounding liver (n = 7), low- (n = 4) and high-grade (n = 9) dysplastic lesions, eHCC (n = 5) and pHCC (n = 3) from 8 HCC patients with hepatitis B infection. Integrative analyses of genetic and transcriptomic changes were performed to characterize the genomic alterations during hepatocarcinogenesis.
We report that changes in transcriptomes of early lesions including eHCC were modest and surprisingly homogenous. Extensive genetic alterations and subsequent activation of prognostic adverse signaling pathways occurred only late during hepatocarcinogenesis and were centered on TGFβ, WNT, NOTCH, and EMT-related genes highlighting the molecular diversity of pHCC. We further identify IGFALS as a key genetic determinant preferentially down-regulated in pHCC.
Our results define new hallmarks in molecular stratification and therapy options for patients at risk for HCC, and merit larger prospective investigations to develop a modified clinical-decision making algorithm based on the individualized next-generation sequencing analyses.
人类肝癌发生是一个多步骤的过程,从发育不良病变开始,进展为早期肝癌(eHCC),最终进展为肝细胞癌(pHCC)。然而,驱动前肿瘤病变恶性转化的连续分子改变尚不清楚。这种信息的缺乏是高危患者临床管理的主要挑战。
我们应用下一代转录组测序技术对 8 例乙型肝炎感染的 HCC 患者的无肿瘤周围肝脏(n=7)、低级别(n=4)和高级别(n=9)发育不良病变、eHCC(n=5)和 pHCC(n=3)进行了分析。对遗传和转录组变化进行综合分析,以描述肝癌发生过程中的基因组改变。
我们报告称,包括 eHCC 在内的早期病变的转录组变化是适度的,而且出人意料地具有同质性。广泛的遗传改变和随后的预后不良信号通路的激活仅在肝癌发生的晚期发生,并集中在 TGFβ、WNT、NOTCH 和 EMT 相关基因上,突出了 pHCC 的分子多样性。我们进一步确定 IGFALS 是 pHCC 中优先下调的关键遗传决定因素。
我们的研究结果为 HCC 高危患者的分子分层和治疗选择提供了新的标志物,并值得进行更大规模的前瞻性研究,以根据个体化的下一代测序分析制定改良的临床决策算法。